Takigawa, N.; Ochi, N.; Nakagawa, N.; Nagasaki, Y.; Taoka, M.; Ichiyama, N.; Mimura, A.; Nakanishi, H.; Kohara, H.; Yamane, H.
Do Elderly Lung Cancer Patients Aged ≥75 Years Benefit from Immune Checkpoint Inhibitors? Cancers 2020, 12, 1995.
https://doi.org/10.3390/cancers12071995
AMA Style
Takigawa N, Ochi N, Nakagawa N, Nagasaki Y, Taoka M, Ichiyama N, Mimura A, Nakanishi H, Kohara H, Yamane H.
Do Elderly Lung Cancer Patients Aged ≥75 Years Benefit from Immune Checkpoint Inhibitors? Cancers. 2020; 12(7):1995.
https://doi.org/10.3390/cancers12071995
Chicago/Turabian Style
Takigawa, Nagio, Nobuaki Ochi, Nozomu Nakagawa, Yasunari Nagasaki, Masataka Taoka, Naruhiko Ichiyama, Ayaka Mimura, Hidekazu Nakanishi, Hiroyuki Kohara, and Hiromichi Yamane.
2020. "Do Elderly Lung Cancer Patients Aged ≥75 Years Benefit from Immune Checkpoint Inhibitors?" Cancers 12, no. 7: 1995.
https://doi.org/10.3390/cancers12071995
APA Style
Takigawa, N., Ochi, N., Nakagawa, N., Nagasaki, Y., Taoka, M., Ichiyama, N., Mimura, A., Nakanishi, H., Kohara, H., & Yamane, H.
(2020). Do Elderly Lung Cancer Patients Aged ≥75 Years Benefit from Immune Checkpoint Inhibitors? Cancers, 12(7), 1995.
https://doi.org/10.3390/cancers12071995